IL37 and influenza: These results demonstrate that intravenous IL-37 administration at 2 h.p.i significantly decreases the mortality of mice infected with H1N1 and shortens the recovery time of infected mice, so intravenous IL-37 administration at 2 h.p.i offers enhanced protection against influenza challenge in mice.